Q2 Earnings Estimate for Repligen Issued By Leerink Partnrs

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Tuesday, April 29th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings of $0.39 per share for the quarter, down from their prior estimate of $0.42. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q3 2025 earnings at $0.39 EPS, FY2025 earnings at $1.67 EPS and FY2026 earnings at $2.14 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the prior year, the company earned $0.28 EPS. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group reduced their target price on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Royal Bank of Canada cut their price objective on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research report on Wednesday. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research note on Tuesday. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Stock Down 0.6 %

RGEN opened at $137.20 on Friday. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business’s fifty day simple moving average is $138.22 and its 200 day simple moving average is $145.83. The stock has a market cap of $7.70 billion, a PE ratio of -269.02, a P/E/G ratio of 4.54 and a beta of 1.27.

Institutional Trading of Repligen

Several institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the period. Point72 Asset Management L.P. lifted its stake in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after acquiring an additional 594,189 shares in the last quarter. Groupama Asset Managment boosted its position in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after acquiring an additional 400,680 shares during the period. Alyeska Investment Group L.P. purchased a new position in Repligen during the 4th quarter valued at about $53,428,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Repligen in the fourth quarter worth approximately $52,492,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.